New developments in adult congenital heart disease

Congenital heart disease (CHD) affects 0.8% of live births and over the past decades technical improvements and large-scale repair has led to increased survival into adulthood of over 95% of the new-born. A new group of patients, those who survived their congenital heart defect, has emerged but late...

Full description

Saved in:
Bibliographic Details
Published inNetherlands heart journal Vol. 28; no. Suppl 1; pp. 44 - 49
Main Authors Bouma, B. J., Sieswerda, G. T., Post, M. C., Ebels, T., van Kimmenade, R., de Winter, R. J., Mulder, B. J.
Format Journal Article
LanguageEnglish
Published Houten Bohn Stafleu van Loghum 01.08.2020
Springer Nature B.V
Subjects
Biomarkers
Cardiology
Cardiovascular disease
Congenital diseases
Medical Education
Medicine
Medicine & Public Health
Mortality
Review
Review Article
GUCH
Congenital heart disease
Adults
Interventions
Cardiac surgery
New developments
Online AccessGet full text

Cover

More Information
Summary:Congenital heart disease (CHD) affects 0.8% of live births and over the past decades technical improvements and large-scale repair has led to increased survival into adulthood of over 95% of the new-born. A new group of patients, those who survived their congenital heart defect, has emerged but late complications including heart failure, pulmonary hypertension (PH), arrhythmias, aneurysms and endocarditis appeared numerous, with a huge impact on mortality and morbidity. However, innovations over the past years have changed the landscape of adult CHD dramatically. In the diagnostic process important improvements have been made in the use of MRI, biomarkers, e‑health concepts and 3D visualisation of anatomy. Care is now concentrated in specialised centres, with a continuous emphasis on education and the introduction of weekly multidisciplinary consultations on diagnosis and intervention. Surgery and percutaneous intervention have been refined and new concepts applied, further reducing the burden of the congenital malformations. Research has matured from case series to global networks. Currently, adults with CHD are still facing high risks of early mortality and morbidity. By global collaboration and continuous education and development and innovation of our diagnostic and therapeutic arsenal, we will improve the perspectives of these young patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-020-01455-5